These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 728866)

  • 1. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma.
    Krown SE; Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Huvos AG; Oettgen HF
    Cancer; 1978 Dec; 42(6):2648-60. PubMed ID: 728866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
    Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
    Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intralesional immune therapy: methanol extraction residue of BCG or purified protein derivative.
    Lokich JJ; Garnick MB; Legg M
    Oncology; 1979; 36(5):236-41. PubMed ID: 481845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of methanol extraction residue of BCG on the cellular immune response in patients with malignant melanoma.
    Bartal A; Cohen Y; Mekori T; Haasz R; Robinson E
    Med Pediatr Oncol; 1979; 6(1):1-10. PubMed ID: 440203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma.
    Nathanson L; Schoenfeld D; Regelson W; Colsky J; Mittelman A
    Cancer; 1979 May; 43(5):1630-5. PubMed ID: 376098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re-inventing intratumoral immunotherapy for melanoma.
    Triozzi PL; Tuthill RJ; Borden E
    Immunotherapy; 2011 May; 3(5):653-71. PubMed ID: 21554094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R; Wybran J; Epstein W
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection.
    McKhann CF; Hendrickson CG; Spitler LE; Gunnarsson A; Banerjee D; Nelson WR
    Cancer; 1975 Feb; 35(2):514-20. PubMed ID: 234291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
    Berd D; Mastrangelo MJ
    Cancer Invest; 1988; 6(3):337-49. PubMed ID: 3167614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple cutaneous malignant melanomas with features of primary melanoma.
    Unger SW; Wanebo HJ; Cooper PH
    Ann Surg; 1981 Feb; 193(2):245-50. PubMed ID: 7469560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy.
    de la Monte SM; Hutchins GM
    Am J Dermatopathol; 1986 Aug; 8(4):331-5. PubMed ID: 3532854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
    MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
    Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulomatous lymphangitis. A complication of intralymphatic immunotherapy with methanol extraction residue of BCG (MER).
    Kirkwood JM; Ariyan S; Nordlund JJ; Forget BM
    Cancer; 1982 Oct; 50(7):1299-303. PubMed ID: 7104973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined-modality treatment of inoperable lung cancer (i.v. immunotherapy, chemotherapy, and radiotherapy).
    Robinson E; Haim N; Segal R; Veseley Z; Mekori T
    Cancer Treat Rep; 1985 Mar; 69(3):251-8. PubMed ID: 2983892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralesional BCG in the treatment of metastatic malignant melanoma.
    Mastrangelo MJ; Sulit HL; Prehn LM; Bornstein RS; Yarbro JW; Prehn RT
    Cancer; 1976 Feb; 37(2):684-92. PubMed ID: 766947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intralesional BCG application in malignant melanoma.
    Sopková B; Kolár V
    Neoplasma; 1976; 23(4):421-6. PubMed ID: 794745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulomatous eruption after BCG vaccine immunotherapy for malignant melanoma.
    Shea CR; Imber MJ; Cropley TG; Cosimi AB; Sober AJ
    J Am Acad Dermatol; 1989 Nov; 21(5 Pt 2):1119-22. PubMed ID: 2681298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guérin and hyperthermic perfusion.
    Storm FK; Sparks FC; Morton DL
    Surg Gynecol Obstet; 1979 Jul; 149(1):17-21. PubMed ID: 451822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary manifestations in patients with malignant melanoma during BCG immunotherapy. A preliminary report.
    Bilgi C; Brown NE; McPherson TA; Lentle B
    Chest; 1979 Jun; 75(6):685-7. PubMed ID: 436519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
    Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
    Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.